2-CHLORO-6-FLUOROPYRIDINE | CAS:20885-12-5

We serve 2-CHLORO-6-FLUOROPYRIDINE CAS:20885-12-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-CHLORO-6-FLUOROPYRIDINE

Chemical Name:    2-CHLORO-6-FLUOROPYRIDINE
CAS.NO: 20885-12-5
Synonyms: 2-Chloro-6-fluoro-pyridine;
2-Chloro-6-Fluoropyridine;
6-chloro-2-fluoropyridine;
pyridine,2-chloro-6-fluoro;
2-Chlor-6-fluorpyridin;
Molecular Formula: C5H3ClFN
Molecular Weight: 131.53500
 
Physical and Chemical Properties:
Density: 1.3±0.1 g/cm3
Melting point: /
Boiling point: 169.2±20.0 °C at 760 mmHg
Flash point: 56.1±21.8 °C
Index of Refraction: 1.503
 
Specification:
Appearance: Light yellow needle
Purity:≥98.0%
 
Packing:25 KGS/Drum
Storage:Store in a tightly closed container. Store in a cool, dry
Application:   used in the Pharmaceutical intermediate



Contact us for information like 2-CHLORO-6-FLUOROPYRIDINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chlor-6-fluorpyridin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Chlor-6-fluorpyridin Use and application,2-CHLORO-6-FLUOROPYRIDINE technical grade,usp/ep/jp grade.


Related News: The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.Furan-2-yl(piperazin-1-yl)methanone hydrochloride manufacturer The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.1-[3,5-bis(trifluoromethyl)phenyl]ethanone supplier “Traditional medicine is a treasure of Chinese civilization embodying the wisdom of the nation and its people,” Xi said at the meeting in Beijing.2-Bromo-6-methylpyridine vendor Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs.”This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.